Jacquemart Renaud, Vandersluis Melissa, Zhao Mochao, Sukhija Karan, Sidhu Navneet, Stout Jim
Natrix Separations Inc., 5295 John Lucas Drive, Burlington, Ontario L7L 6A8, Canada.
Comput Struct Biotechnol J. 2016 Jul 5;14:309-18. doi: 10.1016/j.csbj.2016.06.007. eCollection 2016.
The current processing paradigm of large manufacturing facilities dedicated to single product production is no longer an effective approach for best manufacturing practices. Increasing competition for new indications and the launch of biosimilars for the monoclonal antibody market have put pressure on manufacturers to produce at lower cost. Single-use technologies and continuous upstream processes have proven to be cost-efficient options to increase biomass production but as of today the adoption has been only minimal for the purification operations, partly due to concerns related to cost and scale-up. This review summarizes how a single-use holistic process and facility strategy can overcome scale limitations and enable cost-efficient manufacturing to support the growing demand for affordable biologics. Technologies enabling high productivity, right-sized, small footprint, continuous, and automated upstream and downstream operations are evaluated in order to propose a concept for the flexible facility of the future.
当前专门用于单一产品生产的大型制造设施的加工模式,已不再是实现最佳制造实践的有效方法。新适应症竞争的加剧以及单克隆抗体市场生物类似药的推出,给制造商带来了降低成本生产的压力。一次性技术和连续上游工艺已被证明是提高生物量产量的经济高效选择,但截至目前,这些技术在纯化操作中的应用还非常有限,部分原因是成本和放大生产方面的担忧。本综述总结了一次性整体工艺和设施策略如何能够克服规模限制,并实现经济高效的制造,以满足对价格合理的生物制品不断增长的需求。为了提出未来灵活设施的概念,对能够实现高生产率、尺寸合适、占地面积小、连续且自动化的上游和下游操作的技术进行了评估。